Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>Products>This Product
  Products


EMax Endpoint ELISA Microplate Reader

Product Description
The EMax® Endpoint ELISA Microplate Reader from Molecular Devices, one of the pioneers in microplate detection, offers a ruggedly simple approach to dedicated endpoint assays. A staggering mean time between failure (MTBF) of 20,000 hours is achieved by 97 independent and stationary fiber optics so that the microplate remains stationary during the entire reading cycle, reducing the number of moving parts. No optical alignment needed during the lifetime of the instrument!

Through sequential, single-well illumination, 100% of the available light is directed to each well through the optical fibers to achieve linearity to higher optical densities (ODs) and optimal signal-to-noise ratios. At 5 seconds to read a 96-well endpoint assay, the EMax Microplate Reader has both the speed and performance to carry a heavy workload.

The EMax Microplate Reader is capable of reading up to two wavelengths at a time in the visible wavelength spectrum (400nm-750nm), with 4 filter choices included at time of purchase. Additional high-quality filters to supplement your assay wavelength range requirements are available directly from Molecular Devices.
Product EMax Endpoint ELISA Microplate Reader
Company Molecular Devices Product Directory
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices Product Directory
1311 Orleans Drive Sunnyvale, CA 94089-11361 United States

Tel: 1-800-635-5577
Fax: 1-408-548-6439
Email: om@moldev.com



Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!